Non-Small Cell Lung Cancer Market to Perceive Excellent CAGR of 13.9%, Trends, Opportunities, & Forecast 2030

Being a detailed market research report,  Non-Small Cell Lung Cancer Market document furnishes the business and gives competitive advantage. This market research report brings into picture comprehensive analysis of the market structure along with estimations of the various segments and sub-segments of the market for Healthcare industry. This market report gives clear idea about strategic analysis of mergers, expansions, acquisitions, partnerships, and investment. The world class Non-Small Cell Lung Cancer Market report also lends a hand to know about the types of consumers, their response and views about particular products, and their thoughts for the step up of a product.

According to data published by the Institute for Clinical and Economic Review (ICER) and the National Institutes of Health (NIH), approximately 85% of lung cancer cases in the United States are NSCLC. Squamous cell carcinoma accounted for 30% of the cases, adenocarcinoma accounted for 40%, and large-cell carcinoma accounted for 15%. Furthermore, all other country-based registries reported nearly the same percentage of NSCLC and its major subtypes.

Data Bridge Market Research analyses that the non-small cell lung cancer market which is USD 26948.36 million in 2022, is expected to reach USD 76334.72 million by 2030, at a CAGR of 13.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Visit full Study Report @ https://www.databridgemarketresearch.com/reports/global-non-small-cell-lung-cancer-market

Non-small cell lung carcinoma (NSCLC), also known as non-small cell lung cancer, is the most common type of lung cancer. The term "non-small cell" refers to the appearance of cancer cells under a microscope. Small cell lung cancer is named after the size of the cells (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC is less likely to spread than SCLC and has a higher survival rate. The majority of people with early-stage NSCLC survive at least 5 years, but the survival rate is much lower if the cancer has spread to other tissues at the time of diagnosis.

Non-Small Cell Lung Cancer Market Dynamics

Drivers

Increase in Cancer Cases

The global increase in cancer cases boosts the global non-small cell lung cancer market during the forecast period. According to American Cancer Society statistics from 2016, the majority of cases of SCLC occur in people between the ages of 60 and 80, with a global death rate of 30,000 per year. Furthermore, according to WHO data, lung cancer is the second most common cancer in men and women, accounting for 1.59 million deaths in 2012. This boosts market growth.

Rising Demand for Oral Drugs

Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.

Recent Developments

In 2019, Pfizer Inc., a multinational pharmaceutical and biotechnology corporation based in the United States, received European Commission (EC) marketing authorization for the LORVIQUA drug, a monotherapy drug used to treat anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).
In 2021, Daiichi Sankyo received FDA approval for adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal (GEJ) adenocarcinoma.

Some of the major players operating in the non-small cell lung cancer market are:

F. Hoffmann-La Roche Ltd. (Switzerland)
Mylan N.V. (U.S.)
Teva Pharmaceutical Industries Ltd. (Israel)
Sanofi (France)
Pfizer Inc. (U.S.)
GSK plc (U.K.)
Novartis AG (Switzerland)
Bayer AG (Germany)
Lilly (U.S.)
Merck & Co., Inc. (U.S.)
Sun Pharmaceutical Industries Ltd. (India)
Aurobindo Pharma (India)
Lupin (India)
CLOVIS ONCOLOGY (U.S.)
Johnson & Johnson Private Limited (U.S.)

Global Non-Small Cell Lung Cancer Market Scope

The non-small cell lung cancer market is segmented on the basis of cancer type, molecule type, drug class, treatment type, therapy type, end user and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Cancer Type

Non-Small Cell Lung Cancer
Metastatic Lung Cancer
Pulmonary Neuroendocrine Tumours
Mediastina Tumours
Mesothelioma
Chest Wall Tumours

 Type

Adenocarcinomas
Squamous Cell Carcinoma
Large Cell Carcinomas
Others

 Molecule Type

Small Molecules
Biologics

Drug Class

Alkylating Agents
Antimetabolites
EGFR Inhibitors
Mitotic Inhibitors
Multi-kinase Inhibitors
Others

 Treatment Type

Chemotherapy
Radiation Therapy
Targeted Therapy
Immunotherapy
Others

Diagnosis

CT Scan
X-Rays
Sputum Cytology
Bronchoscopy
Laboratory Tests
Thoracoscopy
Others

 Therapy Type

Single Drug Therapy
Combination Therapy

End User

Hospitals
Homecare
Specialty Clinics
Others

 Distribution Channel

Hospital Pharmacy
Retail Pharmacy
Online
Others

Fundamental Aim of Non-Small Cell Lung Cancer Market Report

In the Non-Small Cell Lung Cancer Market, every company has goals, but this report focuses in on the most important ones, allowing you to gain insight into the competition, the future of the market, potential new products, and other useful information that can boost your sales significantly.

Factors influencing the Non-Small Cell Lung Cancer Market Size and growth rate.
Major alterations to the Non-Small Cell Lung Cancer Market in the near future.
Notable Market rivals around the world.
The Non-Small Cell Lung Cancer Market's Future Scope and Product Outlook
Future-promising emerging markets.
The Market Presents Difficult Challenges and Threats.
Sales data and profiles of the world's leading Non-Small Cell Lung Cancer Market players

Table of Contents:

Introduction
Market Segmentation
Executive Summary
Premium Insights
Non-Small Cell Lung Cancer Market): Regulations
Market Overview
Non-Small Cell Lung Cancer Market, By Type
Non-Small Cell Lung Cancer Market, By Application
Non-Small Cell Lung Cancer Market, By Route of Administration
Non-Small Cell Lung Cancer Market, End-Users
Non-Small Cell Lung Cancer Market, By Region
Non-Small Cell Lung Cancer Market: Company Landscape
SWOT Analyses
Company Profile
Questionnaires
Related Reports

 Browse More Reports

https://markettreports.blogspot.com/2023/08/europe-ophthalmology-market-key-players.html

https://markettreports.blogspot.com/2023/08/dental-sterilization-market-growth-by.html

https://markettreports.blogspot.com/2023/08/ophthalmology-market-growth-detail.html

https://markettreports.blogspot.com/2023/08/microsurgery-market-industry-analysis.html

About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today!
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact Us:
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email: - corporatesales@databridgemarketresearch.com

This release was published on openPR.